Loading tape…Loading tape…
EW
EW
EW
Edwards Lifesciences Corp recently highlighted growth prospects in a headline stating: 'Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead'. Against this backdrop, the company reports a market capitalization of $51.76 billion alongside full-year revenue of $6.07 billion. These expansion initiatives align with current metrics showing a P/E ratio of 51.67, an EPS (TTM) of 1.74, and a free cash flow yield of 2.77%.
Based on marketbeat.comFirst Citizens Bank & Trust Co. Makes New $792,000 Investment in Edwards Lifesciences Corporation $EW
Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts Stake
Analyzing Elutia (NASDAQ:ELUT) and Edwards Lifesciences (NYSE:EW)
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
Edwards Lifesciences to Host Investor Event in Conjunction With TCT
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.